A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

NCT04630860 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: LY03003

Sponsor

Luye Pharma Group Ltd.